JP7687636B2 - セロトニン１ｂ受容体モジュレーターとしての強力で選択的な新規化合物 - Google Patents

セロトニン１ｂ受容体モジュレーターとしての強力で選択的な新規化合物 Download PDF

Info

Publication number
JP7687636B2
JP7687636B2 JP2023522401A JP2023522401A JP7687636B2 JP 7687636 B2 JP7687636 B2 JP 7687636B2 JP 2023522401 A JP2023522401 A JP 2023522401A JP 2023522401 A JP2023522401 A JP 2023522401A JP 7687636 B2 JP7687636 B2 JP 7687636B2
Authority
JP
Japan
Prior art keywords
methyl
dimethylamino
oxadiazol
ethoxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023522401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547346A (ja
JP2023547346A5 (https=
Inventor
ラリア、フリオ カストロ－パロミノ
ゴメス、フアン アルベルト カマチョ
リスエニョ、ルース ムニョス
クレマン－デマンジェ、リーズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leukos Biotech SL
Original Assignee
Leukos Biotech SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leukos Biotech SL filed Critical Leukos Biotech SL
Publication of JP2023547346A publication Critical patent/JP2023547346A/ja
Publication of JP2023547346A5 publication Critical patent/JP2023547346A5/ja
Application granted granted Critical
Publication of JP7687636B2 publication Critical patent/JP7687636B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023522401A 2020-10-08 2021-10-07 セロトニン１ｂ受容体モジュレーターとしての強力で選択的な新規化合物 Active JP7687636B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382888.4 2020-10-08
EP20382888 2020-10-08
PCT/EP2021/077660 WO2022074103A1 (en) 2020-10-08 2021-10-07 Potent and selctive compounds as serotonin 1b receptor modulators

Publications (3)

Publication Number Publication Date
JP2023547346A JP2023547346A (ja) 2023-11-10
JP2023547346A5 JP2023547346A5 (https=) 2024-07-23
JP7687636B2 true JP7687636B2 (ja) 2025-06-03

Family

ID=73030029

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023522401A Active JP7687636B2 (ja) 2020-10-08 2021-10-07 セロトニン１ｂ受容体モジュレーターとしての強力で選択的な新規化合物

Country Status (21)

Country Link
US (1) US12540133B2 (https=)
EP (2) EP4445901A3 (https=)
JP (1) JP7687636B2 (https=)
KR (1) KR20230107566A (https=)
CN (1) CN116635390B (https=)
AU (1) AU2021356114A1 (https=)
CA (1) CA3194700A1 (https=)
CL (1) CL2023001021A1 (https=)
DK (1) DK4225753T3 (https=)
ES (1) ES2985416T3 (https=)
FI (1) FI4225753T3 (https=)
HR (1) HRP20241184T1 (https=)
HU (1) HUE068199T2 (https=)
IL (1) IL301806B1 (https=)
LT (1) LT4225753T (https=)
MX (1) MX2023004116A (https=)
PL (1) PL4225753T3 (https=)
PT (1) PT4225753T (https=)
RS (1) RS65956B1 (https=)
SI (1) SI4225753T1 (https=)
WO (1) WO2022074103A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR123701A1 (es) 2020-10-08 2023-01-04 Merck Sharp & Dohme Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2
EP4382519A4 (en) * 2021-08-27 2024-12-04 Adlai Nortye Biopharma Co., Ltd. CYCLIN K DEGRADING AGENT
AU2024302643A1 (en) 2023-06-16 2026-01-22 Leukos Biotech Sl 5-htr1b modulator for use in the treatment of solid tumours

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015920A1 (en) 1992-12-30 1994-07-21 Glaxo Group Limited Benzanilide derivatives as 5-ht1d-antagonists
JP2002521377A (ja) 1998-07-20 2002-07-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ビフェニル誘導体
JP2004505070A (ja) 2000-07-31 2004-02-19 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー カルボキサミド化合物およびそれらのヒト１１ｃｂｙ受容体アンタゴニストとしての使用
JP2004527499A (ja) 2001-01-12 2004-09-09 アムジエン・インコーポレーテツド 置換アミン誘導体および血管形成を治療するためのそれらの使用
WO2007077457A2 (en) 2006-01-06 2007-07-12 The Royal Veterinary College Treatment of equine laminitis with 5-ht1b/ 1d antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801170A (en) 1993-12-07 1998-09-01 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5HT1D antagonists
ZA985542B (en) * 1997-07-03 1999-04-07 Smithkline Beecham Corp Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents
WO2007057742A2 (en) 2005-11-18 2007-05-24 Pfizer Products Inc. Novel piperazinone derivatives
EP3348266A1 (en) 2017-01-16 2018-07-18 Leukos Biotech, S.L. Combination therapy for treating cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015920A1 (en) 1992-12-30 1994-07-21 Glaxo Group Limited Benzanilide derivatives as 5-ht1d-antagonists
JP2002521377A (ja) 1998-07-20 2002-07-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ビフェニル誘導体
JP2004505070A (ja) 2000-07-31 2004-02-19 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー カルボキサミド化合物およびそれらのヒト１１ｃｂｙ受容体アンタゴニストとしての使用
JP2004527499A (ja) 2001-01-12 2004-09-09 アムジエン・インコーポレーテツド 置換アミン誘導体および血管形成を治療するためのそれらの使用
WO2007077457A2 (en) 2006-01-06 2007-07-12 The Royal Veterinary College Treatment of equine laminitis with 5-ht1b/ 1d antagonists

Also Published As

Publication number Publication date
HRP20241184T1 (hr) 2024-11-22
DK4225753T3 (da) 2024-08-19
WO2022074103A1 (en) 2022-04-14
MX2023004116A (es) 2023-06-13
EP4225753A1 (en) 2023-08-16
CN116635390A (zh) 2023-08-22
CN116635390B (zh) 2026-03-27
RS65956B1 (sr) 2024-10-31
CL2023001021A1 (es) 2023-11-24
US20240166639A1 (en) 2024-05-23
LT4225753T (lt) 2024-08-26
JP2023547346A (ja) 2023-11-10
IL301806B1 (en) 2026-01-01
EP4445901A2 (en) 2024-10-16
AU2021356114A1 (en) 2023-05-18
AU2021356114A9 (en) 2024-09-12
HUE068199T2 (hu) 2024-12-28
SI4225753T1 (sl) 2024-10-30
PT4225753T (pt) 2024-08-30
EP4225753B1 (en) 2024-07-31
FI4225753T3 (fi) 2024-08-29
KR20230107566A (ko) 2023-07-17
PL4225753T3 (pl) 2024-11-18
US12540133B2 (en) 2026-02-03
EP4445901A3 (en) 2024-12-04
IL301806A (en) 2023-05-01
ES2985416T3 (es) 2024-11-05
CA3194700A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
CN114040911B (zh) 作为nav1.8抑制剂的2,3-二氢喹唑啉化合物
JP7579789B2 (ja) 免疫調節剤、組成物およびその使用方法
CN113214287B (zh) Hpk1抑制剂及其使用方法
JP2023126907A (ja) Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
CA2799146C (en) Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine
JP7687636B2 (ja) セロトニン１ｂ受容体モジュレーターとしての強力で選択的な新規化合物
JP2023536948A (ja) Ｅｇｆｒ阻害剤およびその製造方法と応用
CN102369187A (zh) 用作wnt信号调节剂的n-(杂)芳基、2-(杂)芳基取代的乙酰胺类
JP2009504804A5 (https=)
JP2021512055A (ja) Ｔａｍファミリーキナーゼ／及びｃｓｆ１ｒキナーゼ阻害剤及びその用途
TWI891753B (zh) 醯胺類化合物及其用途
WO2018214866A1 (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
JPWO2016098793A1 (ja) 環状グアニジル基を有するチアゾール誘導体
WO2023155900A1 (zh) 一类五元并六元杂环化合物及其作为蛋白激酶抑制剂的用途
JP2024516194A (ja) Ｐｄ１／ｐｄ－ｌ１阻害剤としての化合物及びその方法
HK40057478B (zh) Hpk1抑制剂及其使用方法
HK40109089A (zh) 酰胺类化合物及其用途
HK40105207A (zh) 酰胺类化合物及其用途
HK40104416A (zh) 酰胺类化合物及其用途
HK40082804B (zh) 酰胺类化合物及其用途
HK40011175B (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
HK40011175A (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240712

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250409

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250514

R150 Certificate of patent or registration of utility model

Ref document number: 7687636

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150